SCHEMBL3097341

SCHEMBL3097341

COc1ccc(Cn2c(Cl)[c]c3ccccc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 1/20 0.54
KDM4E B2RXH2 5/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
GAA P10253 3/20 0.50
POLB P06746 1/20 0.50
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 4/20 0.49
HTT P42858 4/20 0.49
LMNA P02545 3/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
CNR2 P34972 1/20 0.49
MAPT P10636 4/20 0.49
ALOX15 P16050 1/20 0.49
TP53 P04637 3/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
SIGMAR1 Q99720 1/20 0.45
GABRA5 P31644 1/20 0.45
HPGD P15428 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3088631 0.85 P2RX4 (0.54) P2RX4KDM4ESMN1; SMN2GAAPOLB
SCHEMBL3088034 0.83 P2RX4 (0.50) P2RX4KDM4ESMN1; SMN2GAAPOLB
SCHEMBL15062740 0.83 TNF (0.50) KDM4ESMN1; SMN2POLBMAPK1ALDH1A1
SCHEMBL3084692 0.81 ALOX5AP (0.45) SMN1; SMN2GAAALDH1A1MAPTTP53
SCHEMBL4381040 0.80 ALDH1A1 (0.48) KDM4ESMN1; SMN2POLBMAPK1ALDH1A1
SCHEMBL3085744 0.79 DRD2 (0.46) SMN1; SMN2POLBALDH1A1KMT2AMEN1
SCHEMBL18356958 0.74 P2RX4 (0.82) P2RX4KDM4ESMN1; SMN2GAAPOLB
SCHEMBL30616070 0.74 P2RX4 (0.82) P2RX4KDM4ESMN1; SMN2GAAPOLB
SCHEMBL3091133 0.72 P2RX4 (0.48) P2RX4KDM4ESMN1; SMN2GAAPOLB
SCHEMBL1304130 0.71 SMN1; SMN2 (0.71) KDM4ESMN1; SMN2GAAALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR P2RX4 1442/4885KDM4E 2711/4885SMN1; SMN2 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.